{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:45:29Z","timestamp":1767836729889,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"the National Key R&D Program of China","award":["2021YFC2702005"],"award-info":[{"award-number":["2021YFC2702005"]}]},{"name":"the National Key R&D Program of China","award":["2023YFC2706101"],"award-info":[{"award-number":["2023YFC2706101"]}]},{"name":"Beijing Hospitals Authority\u2019s Ascent Plan","award":["DFL20221001"],"award-info":[{"award-number":["DFL20221001"]}]},{"name":"Beijing Municipal Hospital Scientific Research and Cultivation Program","award":["PX2023043"],"award-info":[{"award-number":["PX2023043"]}]},{"name":"the Young Scientists Fund of the National Natural Science Foundation of China","award":["82404757"],"award-info":[{"award-number":["82404757"]}]},{"name":"Tianchi Talent Program of Xinjiang Uygur Autonomous Region"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40268-025-00506-9","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:11:38Z","timestamp":1744359098000},"page":"79-88","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of Sirolimus Blood Concentration and Influencing Factors in Pediatric Patients: Implications for Individualized Drug Therapy"],"prefix":"10.1007","volume":"25","author":[{"given":"Xiaolin","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueting","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huawei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"506_CR1","first-page":"26","volume":"6","author":"M Zhu","year":"2005","unstructured":"Zhu M, Guo DH. Sirolimus, a new macrolide immunosuppressant. Chin J Drug Appl Monit. 2005;6:26\u20138.","journal-title":"Chin J Drug Appl Monit."},{"issue":"7","key":"506_CR2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.13201\/j.issn.1004-2806.2021.07.006","volume":"34","author":"H Gu","year":"2021","unstructured":"Gu H, Chen ZP, Ma J, et al. Effective and safe treatment of sirolimus in the childhood autoimmune lymphoproliferative syndrome with hemocytopenia- a single center, retrospective cohort study. J Clin Hematol (China). 2021;34(7):477\u201382. https:\/\/doi.org\/10.13201\/j.issn.1004-2806.2021.07.006.","journal-title":"J Clin Hematol (China)"},{"issue":"1","key":"506_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4274\/tjh.galenos.2021.2020.0724","volume":"38","author":"B Koluk\u0131sa","year":"2021","unstructured":"Koluk\u0131sa B, Bar\u0131\u015f S. Primary immune regulatory disorders and targeted therapies. Turk J Haematol. 2021;38(1):1\u201314. https:\/\/doi.org\/10.4274\/tjh.galenos.2021.2020.0724.","journal-title":"Turk J Haematol"},{"key":"506_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.clim.2016.07.017","volume":"171","author":"W Rae","year":"2016","unstructured":"Rae W, Ramakrishnan KA, Gao Y, et al. Precision treatment with sirolimus in a case of activated phosphoinositide 3-kinase \u03b4 syndrome. Clin Immunol. 2016;171:38\u201340. https:\/\/doi.org\/10.1016\/j.clim.2016.07.017.","journal-title":"Clin Immunol"},{"issue":"8","key":"506_CR5","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s10875-018-0568-x","volume":"38","author":"Y Wang","year":"2018","unstructured":"Wang Y, Wang W, Liu L, et al. Report of a Chinese cohort with activated phosphoinositide 3-kinase \u03b4 syndrome. J Clin Immunol. 2018;38(8):854\u201363. https:\/\/doi.org\/10.1007\/s10875-018-0568-x.","journal-title":"J Clin Immunol"},{"issue":"6","key":"506_CR6","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3349\/ymj.2020.61.6.542","volume":"61","author":"JM Kang","year":"2020","unstructured":"Kang JM, Kim SK, Kim D, et al. Successful sirolimus treatment for Korean patients with activated phosphoinositide 3-kinase \u03b4 syndrome 1: the first case series in Korea. Yonsei Med J. 2020;61(6):542\u20136. https:\/\/doi.org\/10.3349\/ymj.2020.61.6.542.","journal-title":"Yonsei Med J"},{"issue":"07","key":"506_CR7","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3969\/j.issn.1008-049X.2011.07.010","volume":"14","author":"Y Xiong","year":"2011","unstructured":"Xiong Y, Wu CX, Li Q, et al. Monitoring analysis of whole blood sirolimus concentrations in renal transplant patients. China Pharm. 2011;14(07):941\u20134. https:\/\/doi.org\/10.3969\/j.issn.1008-049X.2011.07.010.","journal-title":"China Pharm."},{"issue":"30","key":"506_CR8","first-page":"2839","volume":"22","author":"J Mou","year":"2011","unstructured":"Mou J, Fu XH, Ren B, et al. Correlation between therapeutic efficacy, adverse drug reaction and plasma concentration of sirolimus in the treatment of reject reaction after renal transplantation. China Pharm. 2011;22(30):2839\u201341.","journal-title":"China Pharm."},{"key":"506_CR9","first-page":"445","volume":"5","author":"MZ Huang","year":"2014","unstructured":"Huang MZ, Hu XJ, Chen JC, et al. Evaluation the methods for the determination of blood sirolimus concentrations and its clinical application. Chin J Clin Pharmacol. 2014;5:445\u20137.","journal-title":"Chin J Clin Pharmacol."},{"issue":"5","key":"506_CR10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/FTD.0000000000000313","volume":"38","author":"KO Zimmerman","year":"2016","unstructured":"Zimmerman KO, Wu H, Greenberg R, et al. Therapeutic drug monitoring, electronic health records, and pharmacokinetic modeling to evaluate sirolimus drug exposure\u2013response relationships in renal transplant patients. Ther Drug Monit. 2016;38(5):600\u20136. https:\/\/doi.org\/10.1097\/FTD.0000000000000313.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"506_CR11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/17425255.2017.1239708","volume":"13","author":"G Fernandes-Silva","year":"2017","unstructured":"Fernandes-Silva G, Ivani de Paula M, Rangel \u00c9B. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions. Expert Opin Drug Metab Toxicol. 2017;13(4):367\u201385. https:\/\/doi.org\/10.1080\/17425255.2017.1239708.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"506_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1078155215624263","volume":"23","author":"JA Wasko","year":"2017","unstructured":"Wasko JA, Westholder JS, Jacobson PA. Rifampin-sirolimus-voriconazole interaction in a hematopoietic cell transplant recipient. J Oncol Pharm Pract. 2017;23(1):75\u20139. https:\/\/doi.org\/10.1177\/1078155215624263.","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"506_CR13","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1016\/j.transproceed.2004.10.056","volume":"36","author":"B S\u00e1daba","year":"2004","unstructured":"S\u00e1daba B, Campanero MA, Quetglas EG, Azanza JR. Clinical relevance of sirolimus drug interactions in transplant patients. Transplant Proc. 2004;36(10):3226\u20138. https:\/\/doi.org\/10.1016\/j.transproceed.2004.10.056.","journal-title":"Transplant Proc"},{"issue":"9","key":"506_CR14","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1016\/j.transproceed.2004.09.043","volume":"36","author":"AS Mathis","year":"2004","unstructured":"Mathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transplant Proc. 2004;36(9):2708\u20139. https:\/\/doi.org\/10.1016\/j.transproceed.2004.09.043.","journal-title":"Transplant Proc"},{"issue":"3","key":"506_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3969\/j.issn.1673-5501.2022.03.012","volume":"17","author":"XL Xu","year":"2022","unstructured":"Xu XL, Han TX, Cheng XL, et al. Analysis of the fluctuation of blood concentration in children using sirlimus: a case report. Chin J Evid Based Pediatr. 2022;17(3):235\u20139. https:\/\/doi.org\/10.3969\/j.issn.1673-5501.2022.03.012.","journal-title":"Chin J Evid Based Pediatr."},{"issue":"2","key":"506_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1592\/phco.26.2.289","volume":"26","author":"A Said","year":"2006","unstructured":"Said A, Garnick JJ, Dieterle N, Peres E, Abidi MH, Ibrahim RB. Sirolimus-itraconazole interaction in a hematopoietic stem cell transplant recipient. Pharmacotherapy. 2006;26(2):289\u201395. https:\/\/doi.org\/10.1592\/phco.26.2.289.","journal-title":"Pharmacotherapy"},{"issue":"12","key":"506_CR17","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/j.1552-4604.1996.tb04162.x","volume":"36","author":"WJ Jusko","year":"1996","unstructured":"Jusko WJ, Ferron GM, Mis SM, Kahan BD, Zimmerman JJ. Pharmacokinetics of prednisolone during administration of sirolimus in patients with renal transplants. J Clin Pharmacol. 1996;36(12):1100\u20136. https:\/\/doi.org\/10.1002\/j.1552-4604.1996.tb04162.x.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"506_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1046\/j.1365-2125.2002.01594.x","volume":"54","author":"L B\u00e4ckman","year":"2002","unstructured":"B\u00e4ckman L, Kreis H, Morales JM, Wilczek H, Taylor R, Burke JT. Sirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients. Br J Clin Pharmacol. 2002;54(1):65\u20138. https:\/\/doi.org\/10.1046\/j.1365-2125.2002.01594.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"4\u20135","key":"506_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ejps.2008.12.007","volume":"36","author":"C Zimmermann","year":"2009","unstructured":"Zimmermann C, van Waterschoot RAB, Harmsen S, et al. PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009;36(4\u20135):565\u201371. https:\/\/doi.org\/10.1016\/j.ejps.2008.12.007.","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"506_CR20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1124\/dmd.30.9.1029","volume":"30","author":"W El-Sankary","year":"2002","unstructured":"El-Sankary W, Bombail V, Gibson GG, Plant N. Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metab Dispos. 2002;30(9):1029\u201334. https:\/\/doi.org\/10.1124\/dmd.30.9.1029.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"506_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1124\/mol.58.2.361","volume":"58","author":"JM Pascussi","year":"2000","unstructured":"Pascussi JM, Drocourt L, Fabre JM, et al. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol. 2000;58(2):361\u201372. https:\/\/doi.org\/10.1124\/mol.58.2.361.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"506_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/aapsj060428","volume":"6","author":"JJ Zimmerman","year":"2004","unstructured":"Zimmerman JJ. Exposure\u2013response relationships and drug interactions of sirolimus. AAPS J. 2004;6(4):1\u201312. https:\/\/doi.org\/10.1208\/aapsj060428.","journal-title":"AAPS J"},{"issue":"10","key":"506_CR23","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/jcph.1423","volume":"59","author":"JB McCrea","year":"2019","unstructured":"McCrea JB, Macha S, Adedoyin A, et al. Pharmacokinetic drug\u2013drug interactions between letermovir and the immunosuppressants cyclosporine, tacrolimus, sirolimus, and mycophenolate mofetil. J Clin Pharm. 2019;59(10):1331\u20139. https:\/\/doi.org\/10.1002\/jcph.1423.","journal-title":"J Clin Pharm"},{"key":"506_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pediatrneurol.2024.08.009","volume":"161","author":"LL Becker","year":"2024","unstructured":"Becker LL, Agricola K, Ritter DM, Krueger DA, Franz DN. Mammalian target of rapamycin inhibitor levels decrease under cenobamate treatment. Pediatr Neurol. 2024;161:73\u20135. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.08.009.","journal-title":"Pediatr Neurol"},{"issue":"9","key":"506_CR25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1097\/TP.0b013e31826b55e2","volume":"94","author":"WJ Sam","year":"2012","unstructured":"Sam WJ, Chamberlain CE, Lee SJ, Goldstein JA, Hale DA, Mannon RB, Kirk AD, Hon YY. Associations of ABCB1 and IL-10 genetic polymorphisms with sirolimus-induced dyslipidemia in renal transplant recipients. Transplantation. 2012;94(9):971\u20137. https:\/\/doi.org\/10.1097\/TP.0b013e31826b55e2.","journal-title":"Transplantation"},{"issue":"3","key":"506_CR26","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00280-017-3379-5","volume":"80","author":"LC Mbatchi","year":"2017","unstructured":"Mbatchi LC, Gassiot M, Pourquier P, Goberna A, Mahammedi H, Mourey L, Joly F, Lumbroso S, Evrard A, Houede N. Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer. Cancer Chemother Pharmacol. 2017;80(3):653\u20139. https:\/\/doi.org\/10.1007\/s00280-017-3379-5.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"506_CR27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1600-6143.2005.00745.x","volume":"5","author":"D Anglicheau","year":"2005","unstructured":"Anglicheau D, Le Corre D, Lechaton S, Laurent-Puig P, Kreis H, Beaune P, Legendre C, Thervet E. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant. 2005;5(3):595\u2013603. https:\/\/doi.org\/10.1111\/j.1600-6143.2005.00745.x.","journal-title":"Am J Transplant"},{"issue":"2","key":"506_CR28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1046\/j.1399-3046.2003.00137.x","volume":"8","author":"A Tejani","year":"2004","unstructured":"Tejani A, Alexander S, Ettenger R, et al. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. Pediatr Transplant. 2004;8(2):151\u201360. https:\/\/doi.org\/10.1046\/j.1399-3046.2003.00137.x.","journal-title":"Pediatr Transplant"},{"issue":"2","key":"506_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/FTD.0b013e31816ba73a","volume":"30","author":"G Filler","year":"2008","unstructured":"Filler G, Bendrick-Peart J, Christians U. Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther Drug Monit. 2008;30(2):138\u201342. https:\/\/doi.org\/10.1097\/FTD.0b013e31816ba73a.","journal-title":"Ther Drug Monit"},{"issue":"01","key":"506_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.13407\/j.cnki.jpp.1672-108X.2022.01.003","volume":"28","author":"YM Wang","year":"2022","unstructured":"Wang YM, Ma AL, Zhao NM, et al. Blood concentration monitoring and clinical application of sirolimus in children. J Pediatr Pharm. 2022;28(01):10\u20133. https:\/\/doi.org\/10.13407\/j.cnki.jpp.1672-108X.2022.01.003.","journal-title":"J Pediatr Pharm"},{"issue":"19","key":"506_CR31","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.11669\/cpj.2017.19.018","volume":"52","author":"YD Zhang","year":"2017","unstructured":"Zhang YD, Yang M, Wang XR, et al. Analysis of blood concentration monitoring of sirolimus and adverse drug reaction in renal transplantation patients. Chin Pharm J. 2017;52(19):1741\u20135. https:\/\/doi.org\/10.11669\/cpj.2017.19.018.","journal-title":"Chin Pharm J"},{"issue":"24","key":"506_CR32","first-page":"2041","volume":"31","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Wang XJ, Shen ZY. Analysis of therapeutic drug monitoring and clinical application of sirolimus in liver transplantation recipients. Chin J Hosp Pharm. 2011;31(24):2041\u20134.","journal-title":"Chin J Hosp Pharm."},{"issue":"2","key":"506_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1046\/j.1399-3046.2003.00148.x","volume":"8","author":"AD Schachter","year":"2004","unstructured":"Schachter AD, Meyers KE, Spaneas LD, et al. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Pediatr Transplant. 2004;8(2):171\u20137. https:\/\/doi.org\/10.1046\/j.1399-3046.2003.00148.x.","journal-title":"Pediatr Transplant"},{"issue":"6","key":"506_CR34","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3324\/haematol.2014.106260","volume":"99","author":"CL Balduini","year":"2014","unstructured":"Balduini CL, Noris P. Platelet count and aging. Haematologica. 2014;99(6):953\u20135. https:\/\/doi.org\/10.3324\/haematol.2014.106260.","journal-title":"Haematologica"},{"key":"506_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.exger.2017.12.026","volume":"105","author":"E Kraig","year":"2018","unstructured":"Kraig E, Linehan LA, Liang H, et al. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: immunological, physical performance, and cognitive effects. Exp Gerontol. 2018;105:53\u201369. https:\/\/doi.org\/10.1016\/j.exger.2017.12.026.","journal-title":"Exp Gerontol"},{"issue":"12","key":"506_CR36","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3390\/genes11121509","volume":"11","author":"LM de Jong","year":"2020","unstructured":"de Jong LM, Jiskoot W, Swen JJ, Manson ML. distinct effects of inflammation on cytochrome P450 regulation and drug metabolism: lessons from experimental models and a potential role for pharmacogenetics. Genes (Basel). 2020;11(12):1509. https:\/\/doi.org\/10.3390\/genes11121509. (Published 2020 Dec 16).","journal-title":"Genes (Basel)."},{"key":"506_CR37","unstructured":"Li J, Huang H, Chen Y, et al. Influence of the ABCB1 hapotype and CYP3A5 genotypes on the sirolimus dose requirements in Chinese clinical transplant recipients. In: 2014 National Academic Conference of Clinical Pharmacy Branch of Chinese Medical Association."},{"key":"506_CR38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ejps.2018.12.004","volume":"128","author":"T Mizuno","year":"2019","unstructured":"Mizuno T, O\u2019Brien MM, Vinks AA. Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediatric patients with acute lymphoblastic leukemia. Eur J Pharm Sci. 2019;128:209\u201314. https:\/\/doi.org\/10.1016\/j.ejps.2018.12.004.","journal-title":"Eur J Pharm Sci"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00506-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-025-00506-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-025-00506-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T03:14:12Z","timestamp":1745205252000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-025-00506-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["506"],"URL":"https:\/\/doi.org\/10.1007\/s40268-025-00506-9","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"10 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported in part by the National Key R&D Program of China (2021YFC2702005, 2023YFC2706101), the Young Scientists Fund of the National Natural Science Foundation of China (Grant no. 82404757), Beijing Hospitals Authority\u2019s Ascent Plan (DFL20221001), Beijing Municipal Hospital Scientific Research and Cultivation Program (PX2023043), and Tianchi Talent Program of Xinjiang Uygur Autonomous Region. In addition, we thank all study and site staff whose indispensable assistance made the trial feasible to conduct. Furthermore, we would like to thank the anonymous reviewers who contributed to the paper\u2019s improvement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study received approval from the Research Ethics Committee of the Beijing Children\u2019s Hospital (reference number: [2024]-Y-094-D).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are not openly available owing to reasons of sensitivity and are available from the corresponding author upon reasonable request.\u00a0","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"X.M. and X.X. performed the study and analyzed the data. X.M. wrote the manuscript. X.C., X.W., and B.L. were responsible for issuing and collecting scales. H.M. conceived and guided the study and critically revised the manuscript. Y.S. performed methodological support. All authors contributed to the article and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}